| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $39,405,235 ) (Continued on the next page) |
| | 2024 | 2024 | ST JUDE CHILDREN'S RESEARCH HOSPITAL INC | 262 DANNY THOMAS PL | MEMPHIS | TN | 38105-3678 | SHELBY | USA | R01CA260175 | XAF1 IN P53 SIGNALING, APOPTOSIS AND TUMOR SUPPRESSION | 001 | 3 | NIH | 4/17/2024 | $20,817 |
| | 2024 | 2024 | ST JUDE CHILDREN'S RESEARCH HOSPITAL INC | 262 DANNY THOMAS PL | MEMPHIS | TN | 38105-3678 | SHELBY | USA | R01CA260175 | XAF1 IN P53 SIGNALING, APOPTOSIS AND TUMOR SUPPRESSION | 000 | 3 | NIH | 2/7/2024 | $374,693 |
| | 2024 | 2024 | ST JUDE CHILDREN'S RESEARCH HOSPITAL INC | 262 DANNY THOMAS PL | MEMPHIS | TN | 38105-3678 | SHELBY | USA | R01CA259581 | Elucidating the Functional and Mechanistic Roles of LINE-1 Retrotransposons in Myeloid Leukemia | 001 | 4 | NIH | 4/17/2024 | $24,382 |
| | 2024 | 2024 | ST JUDE CHILDREN'S RESEARCH HOSPITAL INC | 262 DANNY THOMAS PL | MEMPHIS | TN | 38105-3678 | SHELBY | USA | R01CA259581 | Elucidating the Functional and Mechanistic Roles of LINE-1 Retrotransposons in Myeloid Leukemia | 000 | 4 | NIH | 12/18/2023 | $438,887 |
| | 2024 | 2024 | ST JUDE CHILDREN'S RESEARCH HOSPITAL INC | 262 DANNY THOMAS PL | MEMPHIS | TN | 38105-3678 | SHELBY | USA | R01AI168214 | Consequences of Direct Viral-Bacterial Interactions | 000 | 3 | NIH | 1/19/2024 | $452,051 |
| | 2024 | 2024 | ST JUDE CHILDREN'S RESEARCH HOSPITAL INC | 262 DANNY THOMAS PL | MEMPHIS | TN | 38105-3678 | SHELBY | USA | K01DK132453 | Defining the mechanisms of hemoglobin switching and genotoxicities associated with its manipulation | 000 | 3 | NIH | 1/4/2024 | $129,319 |
| | 2024 | 2024 | ST JUDE CHILDREN'S RESEARCH HOSPITAL INC | 262 DANNY THOMAS PL | MEMPHIS | TN | 38105-3678 | SHELBY | USA | R01CA262589 | Enhancing B7-H3-CAR T cell therapy for pediatric solid tumors | 001 | 3 | NIH | 4/17/2024 | $37,724 |
| | 2024 | 2024 | ST JUDE CHILDREN'S RESEARCH HOSPITAL INC | 262 DANNY THOMAS PL | MEMPHIS | TN | 38105-3678 | SHELBY | USA | R01CA262589 | Enhancing B7-H3-CAR T cell therapy for pediatric solid tumors | 000 | 3 | NIH | 2/14/2024 | $679,069 |
| | 2024 | 2024 | ST JUDE CHILDREN'S RESEARCH HOSPITAL INC | 262 DANNY THOMAS PL | MEMPHIS | TN | 38105-3678 | SHELBY | USA | R01CA262790 | The Role of Immature Tumor Subpopulations In Pediatric Rhabdomyosarcoma | 001 | 3 | NIH | 4/16/2024 | $20,817 |
| | 2024 | 2024 | ST JUDE CHILDREN'S RESEARCH HOSPITAL INC | 262 DANNY THOMAS PL | MEMPHIS | TN | 38105-3678 | SHELBY | USA | R01CA262790 | The Role of Immature Tumor Subpopulations In Pediatric Rhabdomyosarcoma | 000 | 3 | NIH | 2/7/2024 | $374,693 |
| | 2024 | 2024 | ST JUDE CHILDREN'S RESEARCH HOSPITAL INC | 262 DANNY THOMAS PL | MEMPHIS | TN | 38105-3678 | SHELBY | USA | F32HL164095 | Mechanisms and consequences of sickle cell disease-induced cycling in hematopoietic stem cells | 000 | 3 | NIH | 3/11/2024 | $73,772 |
| | 2024 | 2024 | ST JUDE CHILDREN'S RESEARCH HOSPITAL INC | 262 DANNY THOMAS PL | MEMPHIS | TN | 38105-3678 | SHELBY | USA | R01NS123116 | Interneuron circuits in the spinal motor system | 000 | 4 | NIH | 4/4/2024 | $435,288 |
| | 2024 | 2024 | ST JUDE CHILDREN'S RESEARCH HOSPITAL INC | 262 DANNY THOMAS PL | MEMPHIS | TN | 38105-3678 | SHELBY | USA | R35GM141947 | Pharmacogenetics of Nucleobase and Nucleoside Analog Drugs | 000 | 4 | NIH | 2/5/2024 | $516,960 |
| | 2024 | 2024 | ST JUDE CHILDREN'S RESEARCH HOSPITAL INC | 262 DANNY THOMAS PL | MEMPHIS | TN | 38105-3678 | SHELBY | USA | R01NS121249 | Improving genetically engineered T cells for medulloblastomas | 001 | 4 | NIH | 4/10/2024 | $31,134 |
| | 2024 | 2024 | ST JUDE CHILDREN'S RESEARCH HOSPITAL INC | 262 DANNY THOMAS PL | MEMPHIS | TN | 38105-3678 | SHELBY | USA | R01NS121249 | Improving genetically engineered T cells for medulloblastomas | 000 | 4 | NIH | 2/14/2024 | $400,298 |
| | 2024 | 2024 | ST JUDE CHILDREN'S RESEARCH HOSPITAL INC | 262 DANNY THOMAS PL | MEMPHIS | TN | 38105-3678 | SHELBY | USA | R01GM141694 | Chromatin of repetitive elements | 000 | 4 | NIH | 4/5/2024 | $323,100 |
| | 2024 | 2024 | ST JUDE CHILDREN'S RESEARCH HOSPITAL INC | 262 DANNY THOMAS PL | MEMPHIS | TN | 38105-3678 | SHELBY | USA | R01GM141357 | Molecular Mechanisms Underlying Mammalian NADPH Oxidase Activation and Regulation | 000 | 4 | NIH | 2/7/2024 | $323,100 |
| | 2024 | 2024 | ST JUDE CHILDREN'S RESEARCH HOSPITAL INC | 262 DANNY THOMAS PL | MEMPHIS | TN | 38105-3678 | SHELBY | USA | R01AI153138 | Robust immune tolerance conferred by Foxp3 transcriptional regulation | 000 | 4 | NIH | 12/15/2023 | $403,875 |
| | 2024 | 2024 | ST JUDE CHILDREN'S RESEARCH HOSPITAL INC | 262 DANNY THOMAS PL | MEMPHIS | TN | 38105-3678 | SHELBY | USA | R01NS121114 | Understanding the sequence and structural determinants of phase behavior of ALS-causing proteins | 001 | 4 | NIH | 4/10/2024 | $43,680 |
| | 2024 | 2024 | ST JUDE CHILDREN'S RESEARCH HOSPITAL INC | 262 DANNY THOMAS PL | MEMPHIS | TN | 38105-3678 | SHELBY | USA | R01CA251436 | Mediators Of Arrested Differentiation In Pediatric Rhabdomyosarcoma | 001 | 4 | NIH | 4/16/2024 | $20,531 |
| | 2024 | 2024 | ST JUDE CHILDREN'S RESEARCH HOSPITAL INC | 262 DANNY THOMAS PL | MEMPHIS | TN | 38105-3678 | SHELBY | USA | R01NS121114 | Understanding the sequence and structural determinants of phase behavior of ALS-causing proteins | 000 | 4 | NIH | 1/18/2024 | $561,572 |
| | 2024 | 2024 | ST JUDE CHILDREN'S RESEARCH HOSPITAL INC | 262 DANNY THOMAS PL | MEMPHIS | TN | 38105-3678 | SHELBY | USA | K00CA234924 | Elucidating USP16 function and probing its DUB activity in Down syndrome leukemia | 000 | 6 | NIH | 1/23/2024 | $90,271 |
| | 2024 | 2024 | ST JUDE CHILDREN'S RESEARCH HOSPITAL INC | 262 DANNY THOMAS PL | MEMPHIS | TN | 38105-3678 | SHELBY | USA | R01CA251436 | Mediators Of Arrested Differentiation In Pediatric Rhabdomyosarcoma | 000 | 4 | NIH | 1/5/2024 | $369,546 |
| | 2024 | 2024 | ST JUDE CHILDREN'S RESEARCH HOSPITAL INC | 262 DANNY THOMAS PL | MEMPHIS | TN | 38105-3678 | SHELBY | USA | K08CA255569 | WT1 as an oncogene and therapeutic target in anaplastic Wilms tumor | 000 | 4 | NIH | 12/21/2023 | $194,741 |
| | 2024 | 2024 | ST JUDE CHILDREN'S RESEARCH HOSPITAL INC | 262 DANNY THOMAS PL | MEMPHIS | TN | 38105-3678 | SHELBY | USA | R01HL156647 | Base editing and prime editing for sickle cell disease | 002 | 4 | NIH | 2/2/2024 | $699,352 |
| | 2024 | 2024 | ST JUDE CHILDREN'S RESEARCH HOSPITAL INC | 262 DANNY THOMAS PL | MEMPHIS | TN | 38105-3678 | SHELBY | USA | R01NS116361 | Deciphering the Role of Aberrant Endogenous Retroviral Expression in Onco-histone Driven Glioma | 001 | 3 | NIH | 4/17/2024 | $40,330 |
| | 2024 | 2024 | ST JUDE CHILDREN'S RESEARCH HOSPITAL INC | 262 DANNY THOMAS PL | MEMPHIS | TN | 38105-3678 | SHELBY | USA | R01NS116361 | Deciphering the Role of Aberrant Endogenous Retroviral Expression in Onco-histone Driven Glioma | 000 | 3 | NIH | 12/8/2023 | $518,525 |
| | 2024 | 2024 | ST JUDE CHILDREN'S RESEARCH HOSPITAL INC | 262 DANNY THOMAS PL | MEMPHIS | TN | 38105-3678 | SHELBY | USA | R01CA245301 | Regulation of collagen linearization during cancer progression and metastasis | 001 | 4 | NIH | 4/16/2024 | $20,531 |
| | 2024 | 2024 | ST JUDE CHILDREN'S RESEARCH HOSPITAL INC | 262 DANNY THOMAS PL | MEMPHIS | TN | 38105-3678 | SHELBY | USA | R01CA245301 | Regulation of collagen linearization during cancer progression and metastasis | 000 | 4 | NIH | 2/22/2024 | $369,546 |
| | 2024 | 2024 | ST JUDE CHILDREN'S RESEARCH HOSPITAL INC | 262 DANNY THOMAS PL | MEMPHIS | TN | 38105-3678 | SHELBY | USA | R01CA248432 | Novel Therapeutic Approaches for the Treatment of Neuroblastoma | 003 | 5 | NIH | 4/17/2024 | $1,969 |
| | 2024 | 2024 | ST JUDE CHILDREN'S RESEARCH HOSPITAL INC | 262 DANNY THOMAS PL | MEMPHIS | TN | 38105-3678 | SHELBY | USA | R01CA248432 | Novel Therapeutic Approaches for the Treatment of Neuroblastoma | 002 | 5 | NIH | 4/17/2024 | $20,531 |
| | 2024 | 2024 | ST JUDE CHILDREN'S RESEARCH HOSPITAL INC | 262 DANNY THOMAS PL | MEMPHIS | TN | 38105-3678 | SHELBY | USA | R01CA248432 | Novel Therapeutic Approaches for the Treatment of Neuroblastoma | 001 | 5 | NIH | 3/11/2024 | $35,491 |
| | 2024 | 2024 | ST JUDE CHILDREN'S RESEARCH HOSPITAL INC | 262 DANNY THOMAS PL | MEMPHIS | TN | 38105-3678 | SHELBY | USA | R01CA248432 | Novel Therapeutic Approaches for the Treatment of Neuroblastoma | 000 | 5 | NIH | 3/8/2024 | $369,546 |
| | 2024 | 2024 | ST JUDE CHILDREN'S RESEARCH HOSPITAL INC | 262 DANNY THOMAS PL | MEMPHIS | TN | 38105-3678 | SHELBY | USA | K08CA250418 | Hypertension Intervention to Reduce Osteonecrosis in Children with Acute Lymphoblastic Leukemia | 000 | 5 | NIH | 2/27/2024 | $224,070 |
| | 2024 | 2024 | ST JUDE CHILDREN'S RESEARCH HOSPITAL INC | 262 DANNY THOMAS PL | MEMPHIS | TN | 38105-3678 | SHELBY | USA | R01CA237311 | Epigenetic Reprogramming of T cell Exhaustion To Enhance Tumor Immunotherapy | 001 | 5 | NIH | 4/19/2024 | $20,531 |
| | 2024 | 2024 | ST JUDE CHILDREN'S RESEARCH HOSPITAL INC | 262 DANNY THOMAS PL | MEMPHIS | TN | 38105-3678 | SHELBY | USA | R01CA237311 | Epigenetic Reprogramming of T cell Exhaustion To Enhance Tumor Immunotherapy | 000 | 5 | NIH | 2/22/2024 | $369,546 |
| | 2024 | 2024 | ST JUDE CHILDREN'S RESEARCH HOSPITAL INC | 262 DANNY THOMAS PL | MEMPHIS | TN | 38105-3678 | SHELBY | USA | R01CA246125 | Role of Phase separation by fusion oncoproteins in oncogenesis | 001 | 5 | NIH | 4/17/2024 | $31,127 |
| | 2024 | 2024 | ST JUDE CHILDREN'S RESEARCH HOSPITAL INC | 262 DANNY THOMAS PL | MEMPHIS | TN | 38105-3678 | SHELBY | USA | R01CA246125 | Role of Phase separation by fusion oncoproteins in oncogenesis | 000 | 5 | NIH | 11/23/2023 | $560,279 |
| | 2024 | 2024 | ST JUDE CHILDREN'S RESEARCH HOSPITAL INC | 262 DANNY THOMAS PL | MEMPHIS | TN | 38105-3678 | SHELBY | USA | R37AI105887 | Metabolic checkpoint in dendritic cell subsets and adaptive immunity | 000 | 11 | NIH | 1/26/2024 | $409,500 |
| | 2024 | 2024 | ST JUDE CHILDREN'S RESEARCH HOSPITAL INC | 262 Danny Thomas Pl | Memphis | TN | 38105-3678 | SHELBY | USA | T2331578 | Children's Hospitals Graduate Medical Education Payment Program | 02 | 7 | HRSA | 3/7/2024 | $13,328 |
| | 2024 | 2024 | ST JUDE CHILDREN'S RESEARCH HOSPITAL INC | 262 Danny Thomas Pl | Memphis | TN | 38105-3678 | SHELBY | USA | T2331578 | Children's Hospitals Graduate Medical Education Payment Program | 02 | 7 | HRSA | 3/7/2024 | $56,295 |
| | 2024 | 2024 | ST JUDE CHILDREN'S RESEARCH HOSPITAL INC | 262 Danny Thomas Pl | Memphis | TN | 38105-3678 | SHELBY | USA | T2331578 | Children's Hospitals Graduate Medical Education Payment Program | 00 | 7 | HRSA | 12/6/2023 | $30,654 |
| | 2024 | 2024 | ST JUDE CHILDREN'S RESEARCH HOSPITAL INC | 262 Danny Thomas Pl | Memphis | TN | 38105-3678 | SHELBY | USA | T2331578 | Children's Hospitals Graduate Medical Education Payment Program | 00 | 7 | HRSA | 12/6/2023 | $129,478 |
| | 2024 | 2024 | ST JUDE CHILDREN'S RESEARCH HOSPITAL INC | 262 Danny Thomas Pl | Memphis | TN | 38105-3678 | SHELBY | USA | T2331578 | Children's Hospitals Graduate Medical Education Payment Program | 01 | 7 | HRSA | 1/29/2024 | $60,642 |
| | 2024 | 2024 | ST JUDE CHILDREN'S RESEARCH HOSPITAL INC | 262 Danny Thomas Pl | Memphis | TN | 38105-3678 | SHELBY | USA | T2331578 | Children's Hospitals Graduate Medical Education Payment Program | 01 | 7 | HRSA | 1/29/2024 | $256,140 |
| | 2024 | 2024 | ST JUDE CHILDREN'S RESEARCH HOSPITAL INC | 262 DANNY THOMAS PL | MEMPHIS | TN | 38105-3678 | SHELBY | USA | U01AI144616 | DIVINCI Enrollment Supplement | 002 | 5 | NIH | 2/14/2024 | $0 |
| | 2024 | 2024 | ST JUDE CHILDREN'S RESEARCH HOSPITAL INC | 262 DANNY THOMAS PL | MEMPHIS | TN | 38105-3678 | SHELBY | USA | U01AI144616 | DIVINCI Enrollment Supplement | 001 | 5 | NIH | 1/24/2024 | $896,275 |
| | 2024 | 2024 | ST JUDE CHILDREN'S RESEARCH HOSPITAL INC | 262 DANNY THOMAS PL | MEMPHIS | TN | 38105-3678 | SHELBY | USA | R01NS100939 | Sonic Hedgehog Signaling in Neocortical Growth and Folding | 000 | 6 | NIH | 1/4/2024 | $591,093 |
| | 2024 | 2024 | ST JUDE CHILDREN'S RESEARCH HOSPITAL INC | 262 DANNY THOMAS PL | MEMPHIS | TN | 38105-3678 | SHELBY | USA | R37AI044828 | Survival Function of the Fadd-Caspase-8-Flip Complex - MERIT Extension | 000 | 26 | NIH | 4/8/2024 | $455,000 |
|
